| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Babita Agrawal | |
| P2860 | cites work | Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation | Q24292211 |
| MUC1: a multifunctional cell surface component of reproductive tissue epithelia | Q24633038 | ||
| T cell activation | Q24658051 | ||
| Targeting the mTOR signaling network for cancer therapy | Q24658334 | ||
| Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting | Q26742012 | ||
| A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment | Q26749571 | ||
| CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition | Q26777563 | ||
| Molecular and cellular insights into T cell exhaustion | Q26800047 | ||
| Molecular mechanisms of T cell co-stimulation and co-inhibition | Q26864888 | ||
| Innate and adaptive immune cells in the tumor microenvironment | Q27008342 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| Hypoxia-inducible factors regulate T cell metabolism and function | Q28081650 | ||
| 5-Fluorouracil: mechanisms of action and clinical strategies | Q28201937 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| Structure and function of the cell surface (tethered) mucins | Q28248285 | ||
| Glycolysis inhibition for anticancer treatment | Q28256222 | ||
| The extracellular matrix: a dynamic niche in cancer progression | Q29617793 | ||
| Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 | Q29619280 | ||
| T cell exhaustion | Q29620463 | ||
| LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells | Q30313865 | ||
| Cancer associated fibroblasts in cancer pathogenesis | Q33664004 | ||
| MUC1: a multifaceted oncoprotein with a key role in cancer progression | Q33880143 | ||
| Failure of cancer vaccines: the significant limitations of this approach to immunotherapy | Q34011280 | ||
| What are the hallmarks of cancer? | Q34107625 | ||
| The extracellular matrix at a glance | Q34152843 | ||
| Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. | Q34429912 | ||
| Translating tumor antigens into cancer vaccines | Q34484042 | ||
| Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms | Q35024882 | ||
| Angiogenic and angiostatic factors in the molecular control of angiogenesis. | Q35191425 | ||
| Recurrent antibiotic exposure may promote cancer formation--Another step in understanding the role of the human microbiota? | Q35764221 | ||
| Inhibitory Receptors Beyond T Cell Exhaustion. | Q35783318 | ||
| Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy | Q35833912 | ||
| Obesity and the role of adipose tissue in inflammation and metabolism | Q36392619 | ||
| Anticancer agents that counteract tumor glycolysis. | Q36452381 | ||
| Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer | Q36597391 | ||
| Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α | Q36921665 | ||
| Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow | Q37249025 | ||
| Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells | Q37402534 | ||
| Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma | Q37542216 | ||
| Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling | Q37559049 | ||
| The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers. | Q37612156 | ||
| Role of tumor microenvironment in tumorigenesis | Q37738074 | ||
| Hypoxia and hypoxia inducible factors in cancer stem cell maintenance | Q37768064 | ||
| Fibroblasts and myofibroblasts: what are we talking about? | Q37836316 | ||
| Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity | Q38031978 | ||
| Coinhibitory molecules in autoimmune diseases. | Q38045307 | ||
| Infection and cancer: revaluation of the hygiene hypothesis | Q38093811 | ||
| Targeting lactate metabolism for cancer therapeutics | Q38133722 | ||
| Therapeutic strategies impacting cancer cell glutamine metabolism | Q38139096 | ||
| Tolerance and exhaustion: defining mechanisms of T cell dysfunction | Q38161101 | ||
| TGF-beta in CAF-mediated tumor growth and metastasis | Q38177501 | ||
| MUC1: a novel metabolic master regulator | Q38177983 | ||
| Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. | Q38306509 | ||
| MUC1 (CD227): a multi-tasked molecule | Q38570769 | ||
| Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy | Q38615337 | ||
| PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma | Q38788703 | ||
| The biology and function of fibroblasts in cancer | Q38828825 | ||
| Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. | Q38837469 | ||
| Metformin: An anti-diabetic drug to fight cancer | Q38976526 | ||
| Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. | Q38996594 | ||
| Adipose-derived stromal cells inhibit prostate cancer cell proliferation inducing apoptosis | Q39010508 | ||
| Interplay between Immune Checkpoint Proteins and Cellular Metabolism. | Q39155250 | ||
| Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment | Q39197674 | ||
| The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. | Q39356609 | ||
| Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium | Q40923257 | ||
| T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. | Q41134187 | ||
| Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression | Q41437712 | ||
| The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment | Q42593305 | ||
| Mutagenicity of nitric oxide-releasing compounds in Escherichia coli: effect of superoxide generation and evidence for two mutagenic mechanisms | Q43722177 | ||
| MUC1 mucin is expressed on human T-regulatory cells: function in both co-stimulation and co-inhibition | Q43828225 | ||
| SnapShot: Immune Checkpoint Inhibitors. | Q45939025 | ||
| Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression | Q46215374 | ||
| PD-L1/PD-1: new kid on the "immune metabolic" block. | Q47101171 | ||
| Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. | Q47447695 | ||
| Discovery of IDO1 Inhibitors: From Bench to Bedside | Q47547812 | ||
| The hypoxic tumour microenvironment | Q48181172 | ||
| Metabolic Barriers to T Cell Function in Tumors. | Q50133232 | ||
| MUC1 is a novel costimulatory molecule of human T cells and functions in an AP-1-dependent manner. | Q50961667 | ||
| Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression. | Q51554659 | ||
| Regulation and Function of the PD-L1 Checkpoint. | Q52725238 | ||
| Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy | Q56890639 | ||
| Hyperprogressive disease: recognizing a novel pattern to improve patient management | Q58561264 | ||
| Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers | Q58584052 | ||
| Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy | Q60920815 | ||
| Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma | Q73119286 | ||
| PD-1: an inhibitory immunoreceptor involved in peripheral tolerance | Q73807451 | ||
| Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 | Q74033284 | ||
| Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation | Q77343398 | ||
| Overexpression of MUC1 reconfigures the binding properties of tumor cells | Q77357803 | ||
| MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells | Q78366913 | ||
| The microbiome and cancer | Q87632019 | ||
| The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy | Q88318275 | ||
| mTOR Complex 1 Signaling Regulates the Generation and Function of Central and Effector Foxp3+ Regulatory T Cells | Q89047059 | ||
| Adipocytes Promote Early Steps of Breast Cancer Cell Dissemination via Interleukin-8 | Q90930607 | ||
| Cancer statistics, 2019 | Q90941571 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 23 | |
| P577 | publication date | 2019-08-27 | |
| P1433 | published in | Clinical and translational medicine | Q27724586 |
| P1476 | title | New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota | |
| P478 | volume | 8 |
| Q91642636 | Bugs as Drugs, potential self-regenerated innovative cancer therapeutics approach for global health |
| Q97524171 | Ganoderma lucidum fruiting body extracts inhibit colorectal cancer by inducing apoptosis, autophagy, and G0/G1 phase cell cycle arrest in vitro and in vivo |
| Q92331758 | Roles of transforming growth factor-β and phosphatidylinositol 3-kinase isoforms in integrin β1-mediated bio-behaviors of mouse lung telocytes |
| Q90694690 | Soy Metabolism by Gut Microbiota from Patients with Precancerous Intestinal Lesions |
Search more.